European Union: Food, Drugs, Healthcare, Life Sciences

On 10 September 2025, the Belgian Competition Authority (the BCA) published a communication clarifying the conditions under which pharmaceutical companies may exchange information...

A significant development on the pan-European life sciences front, was the July publication by the European Commission (the "Commission") of its long-awaited Life Sciences Strategy.

Welcome to the third edition of our 2025 Legal & Regulatory Updates, where we bring you the latest developments designed to keep you informed and ahead in a fast-evolving landscape. In this issue, we cover...

Find out 5 key innovation takeaways AstraZeneca shared in our webinar, from ecosystem partnerships to patient impact, and learn how to scale innovation.

The Court of Appeal over-turned the Lisbon LD decision and granted Boehringer Ingelheim's preliminary injunction (PI) application against Zentiva's generic product.

A significant development on the pan-European life sciences front, was the July publication by the European Commission (the "Commission") of its long-awaited Life Sciences Strategy.

Find out 5 key innovation takeaways AstraZeneca shared in our webinar, from ecosystem partnerships to patient impact, and learn how to scale innovation.

Innovation may start with a single idea, but it only becomes transformative when it's scaled through the right networks, partnerships, and ecosystems.

This update (No. 122 | 31 August 2025) covers key policy and regulatory developments related to EU geopolitical risks, including in particular, economic security, Russia's war against Ukraine, health threats, and cyber threats. It does not purport to provide an exhaustive overview of developments.